• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Vor Biopharma Inc.

    3/30/26 8:06:55 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VOR alert in real time by email
    S-8 1 vor-20260327.htm S-8 S-8
    gfx101492977_0.gif

     

     

     

    As filed with the U.S. Securities and Exchange Commission on March 30, 2026

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Vor Biopharma Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware

    81-1591163

    (State or other jurisdiction of

    Incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

     

    500 Boylston Street

    Suite 1350

    Boston, Massachusetts

    02140

    (Address of principal executive offices)

    (Zip code)

     

    Amended and Restated 2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full titles of the plans)

     

    Jean-Paul Kress, M.D.

    President and Chief Executive Officer

    Vor Biopharma Inc.

    500 Boylston Street

    Suite 1350

    Boston, Massachusetts 02116

    (617) 655-6580

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Divakar Gupta

    Madison A. Jones

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001-2157

    (212) 479-6000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

    Pursuant to General Instruction E of Form S-8, this Registration Statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering an additional 1,638,807 shares of common stock, $0.0001 par value per share (the “Common Stock”), of Vor Biopharma Inc. (the “Registrant”), consisting of:

    •
    1,548,807 shares of Common Stock issuable pursuant to the Registrant’s Amended and Restated 2021 Equity Incentive Plan (the “2021 EIP”), pursuant to the provisions of the 2021 EIP providing for an automatic increase in the number of shares reserved and available for issuance under the 2021 EIP on January 1, 2026; and
    •
    90,000 shares of Common Stock issuable pursuant to the Registrant’s 2021 Employee Stock Purchase Plan (the “2021 ESPP”), pursuant to the provisions of the 2021 ESPP providing for an automatic increase in the number of shares reserved and available for issuance under the 2021 ESPP on January 1, 2026.

    In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    PART II

    ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The contents of the Registrant’s Registration Statements on Form S-8, filed with the Commission on February 9, 2021 (File No. 333-252908), March 14, 2022 (File No. 333-263540), March 23, 2023 (File No. 333-270789), March 21, 2024 (File No. 333-278117), March 20, 2025 (File No. 333-285971), and September 24, 2025 (File No. 333-290491);

    (b) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 30, 2026 (File No. 001-39979);

    (c) The Registrant’s Current Report on Form 8-K filed with the Commission on January 2, 2026 (File No. 001-39979) (to the extent the information in such reports is filed and not furnished); and

    (d) The description of the Registrant’s Common Stock, which is contained in Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 30, 2026 (File No. 001-39979), including any amendment or report filed for the purpose of updating such description.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    1


     

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

    As of the date of the date hereof, GC&H Investments, LLC and GC&H Investments, a California partnership, which are entities beneficially owned by current and former partners and associates of Cooley LLP, counsel to the Registrant, beneficially hold an aggregate of 35,350 shares of the Registrant’s common stock.

     

    ITEM 8. EXHIBITS

    Exhibit
    Number

    Description

    Schedule
    Form

    File
    Number

    Exhibit

    Filing Date

    4.1

    Amended and Restated Certificate of Incorporation of the Registrant.

    8-K

    001-39979

    3.1

    February 9, 2021

    4.2

    Certificate of Amendment of Amended and Restated Certificate of Incorporation.

    8-K

    001-39979

    3.1

    May 23, 2025

    4.3

    Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant.

    8-K

    001-39979

    3.1

    September 17, 2025

    4.4

    Amended and Restated Bylaws of the Registrant.

    8-K

    001-39979

    3.2

    February 9, 2021

    4.5

    Form of Common Stock Certificate of the Registrant.

    S-1/A

    333-252175

    4.1

    February 1, 2021

    5.1*

    Opinion of Cooley LLP.

     

     

     

     

    23.1*

    Consent of Cooley LLP (included in Exhibit 5.1).

     

     

     

     

    23.2*

    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.

     

     

     

     

    24.1*

    Power of Attorney (included on the signature page of this registration statement).

     

     

     

     

    99.1

    2021 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement.

    S-1/A

    333-252175

    10.6

    February 1, 2021

      99.2

    Amended and Restated 2021 Equity Incentive Plan.

    8-K

    001-39979

    10.1

    August 27, 2025

    2


     

    Exhibit
    Number

    Description

    Schedule
    Form

    File
    Number

    Exhibit

    Filing Date

      99.3

    2021 Employee Stock Purchase Plan.

    S-1/A

    333-252175

    10.7

    February 1, 2021

    107*

    Filing Fee Table.

     

     

     

     

     

    * Filed herewith

    3


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on March 30, 2026.

    VOR BIOPHARMA INC.

    By: /s/ Jean-Paul Kress

    Jean-Paul Kress, M.D.

    President, Chief Executive Officer and Chairman of the Board

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jean-Paul Kress and Sandesh Mahatme, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

    Signature

    Title

    Date

     

     

     

    /s/ Jean-Paul Kress

    Jean-Paul Kress, M.D.

    President, Chief Executive Officer and Chairman

    of the Board

    (Principal Executive Officer)

    March 30, 2026

     

     

     

     

    /s/ Sandesh Mahatme

    Sandesh Mahatme

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

    March 30, 2026

     

     

     

    /s/ Daniella Beckman

    Daniella Beckman

    Director

     

    March 30, 2026

     

     

     

    /s/ Alexander Cumbo

    Alexander Cumbo

    Director

    March 30, 2026

     

     

     

    /s/ Michel Detheux

    Michel Detheux

    Director

    March 30, 2026

     

     

     

    /s/ Erez Kalir

    Erez Kalir

    Director

    March 30, 2026

     

     

     

    /s/ Wouter Joustra

    Wouter Joustra

    Director

    March 30, 2026

     

     

     

     

     

     

    /s/ Andrew Levin

    Andrew Levin

    Director

    March 30, 2026

     

     

     

    /s/ Fouad Namouni

    Fouad Namouni, M.D.

    Director

    March 30, 2026

     

     


    Get the next $VOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VOR

    DatePrice TargetRatingAnalyst
    3/30/2026$50.00Buy
    Jefferies
    3/19/2026$30.00Overweight
    Wells Fargo
    1/9/2026$50.00Buy
    Citigroup
    12/17/2025Buy
    TD Cowen
    12/9/2025$43.00Overweight
    Analyst
    11/25/2025$9.00Neutral
    Wedbush
    10/15/2025$64.00Neutral → Outperform
    Robert W. Baird
    9/24/2025$55.00Hold → Buy
    Stifel
    More analyst ratings

    $VOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Vor Biopharma with a new price target

    Jefferies initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $50.00

    3/30/26 8:22:03 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wells Fargo initiated coverage on Vor Biopharma with a new price target

    Wells Fargo initiated coverage of Vor Biopharma with a rating of Overweight and set a new price target of $30.00

    3/19/26 8:27:43 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Vor Biopharma with a new price target

    Citigroup initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $50.00

    1/9/26 9:08:27 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Reprogrammed Interchange Llc bought 38,974,101 shares (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    1/2/25 7:42:04 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. gave a grant of 4,625,346 shares (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    12/19/25 6:58:03 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Joustra Wouter

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    12/19/25 6:17:24 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Levin Andrew David

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    12/19/25 6:14:26 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    SEC Filings

    View All

    SEC Form S-8 filed by Vor Biopharma Inc.

    S-8 - Vor Biopharma Inc. (0001817229) (Filer)

    3/30/26 8:06:55 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Vor Biopharma Inc.

    10-K - Vor Biopharma Inc. (0001817229) (Filer)

    3/30/26 8:03:04 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vor Biopharma Inc. (0001817229) (Filer)

    3/27/26 8:03:02 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease $75 million private placement strengthens balance sheet and supports telitacicept global clinical development Pro-forma cash and investment balance of $530.2 million as of December 31, 2025 expected to provide runway into early 2029 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. "Over the past six months, Vor Bio repositioned the compa

    3/30/26 8:01:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

    BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first patient in UPSTREAM SjD, a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating telitacicept in adult patients with active primary Sjögren's disease (SjD), formerly known as Sjögren's syndrome. "Dosing the first patient in the global Phase 3 UPSTREAM SjD trial represents a significant milestone for telitacicept and for patients living with Sjögren's disease. As the only BAFF/APRIL inhibitor currently in Phase 3 development for this condition, we believe telitacicept has th

    3/30/26 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Announces $75 Million Private Placement with TCGX

    BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $75 million, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions. The fin

    3/27/26 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Leadership Updates

    Live Leadership Updates

    View All

    Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

    BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company's recently announced $150M PIPE financing, which included participation from both investors. "Andrew and Wouter bring highly complementary experience in life sciences investment, financing strategy, and board-level oversight. We are delighted to welcome them to our Board at an important moment for the

    12/23/25 4:01:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

    BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development to the company's leadership team. "We are thrilled to welcome Jeremy to Vor Bio," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "His deep clinical expertise as a rheumatologist, coupled with his strong track record in industry and as a thought leader in autoimmune and inflammato

    11/3/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

    CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical affairs, commercial, and R&D functions. He has overseen more than 40 development programs in neurology, immunology, and infectious diseases, and successfully guided seven U.S. and global product launches in rare neurology and immunology indications. Most recently, Dr. Khan was Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where h

    9/23/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Financials

    Live finance-specific insights

    View All

    Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

    Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) reduction vs 19.3% on placebo at 24 weeks Sustained efficacy and favorable safety profile through 48 weeks support potential best-in-disease profile in primary Sjögren's disease (pSD) Company evaluating timing of global Phase 3 clinical study in primary Sjögren's diseaseVor Bio to host a conference call on Tuesday, October 28, 2025 at 4:30PM ET BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-sta

    10/14/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

    CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

    5/8/25 8:30:15 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

    Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a post

    12/9/24 7:30:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    11/14/24 4:33:50 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)

    SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

    2/14/24 4:17:24 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    2/14/24 4:08:06 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care